Cargando…
Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
AIM: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS: BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reac...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871827/ https://www.ncbi.nlm.nih.gov/pubmed/29599607 http://dx.doi.org/10.3748/wjg.v24.i12.1321 |
_version_ | 1783309705947381760 |
---|---|
author | Wongjarupong, Nicha Negron-Ocasio, Gabriela M Chaiteerakij, Roongruedee Addissie, Benyam D Mohamed, Essa A Mara, Kristin C Harmsen, William S Theobald, J Paul Peters, Brian E Balsanek, Joseph G Ward, Melissa M Giama, Nasra H Venkatesh, Sudhakar K Harnois, Denise M Charlton, Michael R Yamada, Hiroyuki Algeciras-Schimnich, Alicia Snyder, Melissa R Therneau, Terry M Roberts, Lewis R |
author_facet | Wongjarupong, Nicha Negron-Ocasio, Gabriela M Chaiteerakij, Roongruedee Addissie, Benyam D Mohamed, Essa A Mara, Kristin C Harmsen, William S Theobald, J Paul Peters, Brian E Balsanek, Joseph G Ward, Melissa M Giama, Nasra H Venkatesh, Sudhakar K Harnois, Denise M Charlton, Michael R Yamada, Hiroyuki Algeciras-Schimnich, Alicia Snyder, Melissa R Therneau, Terry M Roberts, Lewis R |
author_sort | Wongjarupong, Nicha |
collection | PubMed |
description | AIM: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS: BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxyprothrombin (DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios (HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS: During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42 (1.18-5.00), 1.86 (0.98-3.52), and 2.83 (1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48 (1.15-1.91) and 1.59 (1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45 (1.06-1.98) and 1.38 (1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65, 0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant (S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION: BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter (S-LAD). |
format | Online Article Text |
id | pubmed-5871827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-58718272018-03-29 Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models Wongjarupong, Nicha Negron-Ocasio, Gabriela M Chaiteerakij, Roongruedee Addissie, Benyam D Mohamed, Essa A Mara, Kristin C Harmsen, William S Theobald, J Paul Peters, Brian E Balsanek, Joseph G Ward, Melissa M Giama, Nasra H Venkatesh, Sudhakar K Harnois, Denise M Charlton, Michael R Yamada, Hiroyuki Algeciras-Schimnich, Alicia Snyder, Melissa R Therneau, Terry M Roberts, Lewis R World J Gastroenterol Retrospective Cohort Study AIM: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS: BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxyprothrombin (DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios (HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS: During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42 (1.18-5.00), 1.86 (0.98-3.52), and 2.83 (1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48 (1.15-1.91) and 1.59 (1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45 (1.06-1.98) and 1.38 (1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65, 0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant (S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION: BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter (S-LAD). Baishideng Publishing Group Inc 2018-03-28 2018-03-28 /pmc/articles/PMC5871827/ /pubmed/29599607 http://dx.doi.org/10.3748/wjg.v24.i12.1321 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Cohort Study Wongjarupong, Nicha Negron-Ocasio, Gabriela M Chaiteerakij, Roongruedee Addissie, Benyam D Mohamed, Essa A Mara, Kristin C Harmsen, William S Theobald, J Paul Peters, Brian E Balsanek, Joseph G Ward, Melissa M Giama, Nasra H Venkatesh, Sudhakar K Harnois, Denise M Charlton, Michael R Yamada, Hiroyuki Algeciras-Schimnich, Alicia Snyder, Melissa R Therneau, Terry M Roberts, Lewis R Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models |
title | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models |
title_full | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models |
title_fullStr | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models |
title_full_unstemmed | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models |
title_short | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models |
title_sort | model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the balad models |
topic | Retrospective Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871827/ https://www.ncbi.nlm.nih.gov/pubmed/29599607 http://dx.doi.org/10.3748/wjg.v24.i12.1321 |
work_keys_str_mv | AT wongjarupongnicha modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT negronocasiogabrielam modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT chaiteerakijroongruedee modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT addissiebenyamd modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT mohamedessaa modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT marakristinc modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT harmsenwilliams modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT theobaldjpaul modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT petersbriane modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT balsanekjosephg modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT wardmelissam modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT giamanasrah modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT venkateshsudhakark modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT harnoisdenisem modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT charltonmichaelr modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT yamadahiroyuki modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT algecirasschimnichalicia modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT snydermelissar modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT therneauterrym modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels AT robertslewisr modelcombiningpretransplanttumorbiomarkersandtumorsizeshowsmoreutilityinpredictinghepatocellularcarcinomarecurrenceandsurvivalthanthebaladmodels |